Gara Jalqabaatti › Saree Oljoo › Indiana › Indianapolis
Qorannoo klinikaalii Saree Oljoo Indianapolis, IN keessatti
Qorannoo 20 Saree Oljoo f Indianapolis fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Community Health Network, Inc, Indianapolis
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Investigative Clinical R of Indiana, Indianapolis
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2Hojjettoota fayyaa simatamoo
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Namoota walitti qabaa jiraSadarkaa 1/2
- Community Health Network, Indianapolis
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Namoota walitti qabaa jiraSadarkaa 3
- Franciscan Health ( Site 0077), Indianapolis
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Namoota walitti qabaa jira
- Indiana University, Indianapolis
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Indiana University (IU) School of Medicine, Indianapolis
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Namoota walitti qabaa jiraSadarkaa 3
- Indiana University Health University Hospital, Indianapolis
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Namoota walitti qabaa jiraSadarkaa 2
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Namoota walitti qabaa jiraSadarkaa 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- Community Cancer Center East, Indianapolis
- fi 5 dabalataa
HER2 Vaccine for Locally Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianapolis
Exercise in Metastatic Breast Cancer: EMBody
Namoota walitti qabaa jira
- Indiana University Melvin & Bren Simon Cancer Center, Indianapolis
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Namoota walitti qabaa jiraSadarkaa 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health Indianapolis, Indianapolis
- Franciscan Health Mooresville, Mooresville · Miili 16 fagaatti
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Indiana University, Indianapolis
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Indianapolis
NearWave Optical Molecular Monitoring
Namoota walitti qabaa jira
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Namoota walitti qabaa jiraSadarkaa 3
- Franciscan Health Indianapolis, Indianapolis
- Franciscan Health Mooresville, Mooresville · Miili 16 fagaatti
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Community Health Network, Indianapolis
Qorannoo Saree Oljoo magaalota biroo keessatti
- New York City, NYQorannoo 136
- Houston, TXQorannoo 126
- Boston, MAQorannoo 112
- Nashville, TNQorannoo 81
- Los Angeles, CAQorannoo 73
- Edison, NJQorannoo 68
- St. Louis, MOQorannoo 64
- Queens, NYQorannoo 64
- Durham, NCQorannoo 64
- Chicago, ILQorannoo 59
- Philadelphia, PAQorannoo 56
- Dallas, TXQorannoo 55
Qorannoo biroo Indianapolis keessatti
- Kansara Qara'a Non-Small CellQorannoo 32
- Saree (Gosoota Hunda)Qorannoo 24
- Cufama OnneeQorannoo 23
- ObesityQorannoo 20
- Kansara MetastatikiiQorannoo 19
- Kansarii ColorectalQorannoo 18
- Kansarii OvariiQorannoo 17
- Dhibee Onneessaa fi DhiigaQorannoo 17
- Dhibee QaraQorannoo 16
- Diabetes Type 1Qorannoo 14
- Kansa EndometiriyaaliiQorannoo 14
- Dhukkubaa AlzheimerQorannoo 14
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.